June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Pabinger, I.
Author:
Pabst, C.

PS1033 A PROOF OF CONCEPT OF LSD1-INHIBITON IN A PHASE I/II PILOT TRIAL OF TCP AND ATRA IN REFRACTORY / RELAPSED AML PATIENTS NOT ELIGIBLE FOR INTENSIVE THERAPY

Wass, M.; Schlenk, R.F.; Göthert, J.; More

HemaSphere. 3(S1):466-467, June 2019.

Author:
Pabst, T.

S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA

Fagnan, A.; Riera Piqué Borràs, M.; Ignacimouttou, C.; More

HemaSphere. 3(S1):8-9, June 2019.

Author:
Pacelli, C.

PF464 DEFERASIROX DRIVES ROS-MEDIATED DIFFERENTIATION AND INDUCES INTERFERON-STIMULATED GENES EXPRESSION IN HEALTHY HEMATOPOIETIC STEM/PROGENITOR CELLS AND IN LEUKEMIA CELLS

Tataranni, T.; Mazzoccoli, C.; Agriesti, F.; More

HemaSphere. 3(S1):183, June 2019.

Author:
Pachón, J.

PF757 REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE

Espigado, I.; Rodriguez, N.; Labrador, G.; More

HemaSphere. 3(S1):332-333, June 2019.

Author:
Pachter, J.

PS1160 PATTERNS OF DUVELISIB-INDUCED LYMPHOCYTOSIS IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA INCLUDING THOSE WITH HIGH-RISK FACTORS TREATED IN THE DUO TRIAL

Barrientos, J.; Flinn, I.; Davids, M.; More

HemaSphere. 3(S1):526-527, June 2019.

Author:
Paci, C.
Author:
Paciello, G.

PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS

Mancini, M.; Monaldi, C.; De Santis, S.; More

HemaSphere. 3(S1):662-663, June 2019.

Author:
Paciello, M.L.

PS1209 NKG2D AND BCMA-CAR NK CELLS EFFICIENTLY ELIMINATE MULTIPLE MYELOMA CELLS. A COMPREHENSIVE COMPARISON BETWEEN TWO CLINICALLY RELEVANT CARS

Maroto-Martín, E.; Encinas, J.; García-Ortiz, A.; More

HemaSphere. 3(S1):550-551, June 2019.

Author:
Pack, R.
Author:
Packham, G.
Author:
Paczkowska, E.
Author:
Padella, A.

PF197 A NEW CLASSIFICATION OF ACUTE MYELOID LEUKEMIA BASED ON INTEGRATED GENOMICS AND METABOLOMICS

Simonetti, G.; Padella, A.; Mengucci, C.; More

HemaSphere. 3(S1):51, June 2019.

PS928 “3C-UP” A NEW ADULT PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUBGROUP: NOVEL MOLECULAR MARKERS

Ferrari, A.; Vitali, S.; Robustelli, V.; More

HemaSphere. 3(S1):418, June 2019.

PS931 ADULT TRIPLE NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA FUSION DETECTION: CHALLENGING AIM FOR PH- ALTERNATIVE THERAPIES

Ferrari, A.; Vitali, S.; Baldazzi, C.; More

HemaSphere. 3(S1):419-420, June 2019.

PS976 METABOLIC REPROGRAMMING OF ACUTE MYELOID LEUKEMIA STEM- PROGENITOR CELLS AT RELAPSE

Ghetti, M.; Padella, A.; Pazzaglia, M.; More

HemaSphere. 3(S1):439-440, June 2019.

PS997 A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1

Cerchione, C.; Guadagnuolo, V.; Papayannidis, C.; More

HemaSphere. 3(S1):448-449, June 2019.

Author:
Padgeva, T.

PB2014 INTERFERON-FREE ANTIVIRAL THERAPY IN THE TREATMENT OF RELAPSE HEPATITIS C VIRUS ASSOCIATED MARGINAL ZONE LYMPHOMA

Lepkov, S.; Subortceva, I.; Tumian, G.; More

HemaSphere. 3(S1):911, June 2019.

Author:
Padilla, I.
Author:
Padron, E.

S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3(S1):374-375, June 2019.

Author:
Padua, R.-A.
Author:
Pagani, A.
Author:
Pagani, C.

PS1267 ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY

Cattaneo, C.; Gramegna, D.; Busca, A.; More

HemaSphere. 3(S1):580-581, June 2019.

Author:
Pagani, I.S.
Author:
Pagano, L.

PS1267 ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY

Cattaneo, C.; Gramegna, D.; Busca, A.; More

HemaSphere. 3(S1):580-581, June 2019.

PS1276 EPIDEMIOLOGY AND CLINICAL OUTCOME OF FUNGAL INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS

Facchin, G.; Candoni, A.; Busca, A.; More

HemaSphere. 3(S1):584, June 2019.

PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS

Mancini, M.; Monaldi, C.; De Santis, S.; More

HemaSphere. 3(S1):662-663, June 2019.

S1637 A BAL-DRIVEN ANTIMICROBIAL TREATMENT IMPROVES CLINICAL OUTCOME IN HEMATOLOGIC MALIGNANCIES PATIENTS WITH LUNG INFILTRATES DETECTION: A PROSPECTIVE MULTICENTER STUDY OF THE SEIFEM GROUP

Marchesi, F.; Cattaneo, C.; Criscuolo, M.; More

HemaSphere. 3(S1):756-757, June 2019.

PB2161 TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA WITH HIGH DOSES OF CYCLOPHOPHAMIDE, BORTEZOMIB AND DEXAMETHASONE FOLLOWED BY DOUBLE AUTOLOGOUS HSCT

Pagano, L.; Maraglino, A. E. M.; Criscuolo, M.; More

HemaSphere. 3(S1):971, June 2019.

Author:
Pagano, M.A.

PS1145 TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL)

Pagano, M.A.; Tibaldi, E.; Brunati, A.M.; More

HemaSphere. 3(S1):518-519, June 2019.

Author:
Pagel, J.M.

PF383 PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL-WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Mato, A.R.; Barrientos, J.C.; Brander, D.; More

HemaSphere. 3(S1):143-144, June 2019.

PS945 KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3

Shah, B.D.; Bishop, M.R.; Oluwole, O.O.; More

HemaSphere. 3(S1):426, June 2019.

PS1075 ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3(S1):487, June 2019.

PS1148 PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B-CELL MALIGNANCIES

Allan, J.N.; Patel, K.; Mato, A.R.; More

HemaSphere. 3(S1):520, June 2019.

Author:
Pagliardini, T.

S117 THE ROLE OF ANTI-THYMOCYTE GLOBULIN WITH THIOTEPA-BUSULFAN-FLUDARABINE BASED CONDITIONING IN PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANT AND POST-TRANSPLANT CYCLOPHOSPHAMIDE

El-Cheikh, J.; Devillier, R.; Dulery, R.; More

HemaSphere. 3(S1):10-11, June 2019.

PS1241 CHECKPOINT INHIBITOR TREATMENT BEFORE HAPLOIDENTICAL TRANSPLATATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES

Philippis, C. De; Legrande, F.; Bramanti, S.; More

HemaSphere. 3(S1):565-566, June 2019.

PS1246 GRAFT SOURCE AND PRE-TRANSPLANT DISEASE STATUS ARE THE MAIN VARIABLES AFFECTING THE OUTCOME OF T CELL-REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR HODGKIN LYMPHOMA

Mariotti, J.; Devillier, R.; Bramanti, S.; More

HemaSphere. 3(S1):568, June 2019.

Author:
Pagliaro, L.

PF158 TARGETING ONCOGENIC NOTCH1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A NEW SELECTIVE SERCA INHIBITOR CAD204520

Marchesini, M.; Gherli, A.; Winter, A.-M. Lund; More

HemaSphere. 3(S1):31, June 2019.

Author:
Pahl, H.L.

PS1434 GENOMIC LANDSCAPE AND MOLECULAR RISK IN PATIENTS WITH DIPSS LOW- AND INTERMEDIATE-1-RISK PRIMARY MYELOFIBROSIS: A STUDY OF THE GERMAN STUDY GROUP FOR MYELOPROLIFERATIVE NEOPLASMS (GSG-MPN)

Panina, E.; Frank, S.; Pahl, H.L.; More

HemaSphere. 3(S1):661, June 2019.

Author:
PAILLASSA, J.

PS1219 CAUSES OF NON – ELIGIBILITY FOR CD19 CAR T-CELL IMMUNOTHERAPY IN PATIENTS WITH RELAPSE/REFRACTORY DLBCL. EXPERIENCE OF SAINT-LOUIS HOSPITAL

PAILLASSA, J.; BLASI, R. DI; BERNARD, S.; More

HemaSphere. 3(S1):556, June 2019.

S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM

Thieblemont, C.; Legouill, S.; Di Blasi, R.; More

HemaSphere. 3(S1):736-737, June 2019.

Author:
Paina, O.

PS960 BLINATUMOMAB - BASED THERAPIES IN CHILDREN AND ADULTS WITH MRD+ AND R/R B-ALL, EXPERIENCE FROM A SINGLE CENTER (CIC 725)

Markova, I.; Bondarenko, S.; Bondarenko, S.; More

HemaSphere. 3(S1):432, June 2019.

PS960 BLINATUMOMAB - BASED THERAPIES IN CHILDREN AND ADULTS WITH MRD+ AND R/R B-ALL, EXPERIENCE FROM A SINGLE CENTER (CIC 725)

Markova, I.; Bondarenko, S.; Bondarenko, S.; More

HemaSphere. 3(S1):432, June 2019.

PS1286 INVASIVE YEAST INFECTIONS IN HEMATOLOGICAL PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

Popova, M.; Rogacheva, Y.; Volkova, A.; More

HemaSphere. 3(S1):588-589, June 2019.

Author:
Paíno, T.

PS1352 DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS

Puig, N.; Paíno, T.; Pérez, J.J.; More

HemaSphere. 3(S1):617-618, June 2019.

Author:
Paiva, A.

PB1885 GENOMIC CHARACTERIZATION OF CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA: ROLE OF ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (ACGH)

Nascimento, T.; Adão, D.; Oliveira, A.; More

HemaSphere. 3(S1):858-859, June 2019.

Author:
Paiva, B.

S121 SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTES

Botta, C.; Perez, C.; Puig, N.; More

HemaSphere. 3(S1):12-13, June 2019.

PF216 ROLE OF MEASURABLE RESIDUAL DISEASE (MRD) IN REDEFINING COMPLETE RESPONSE (CR) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PETHEMA-FLUGAZA PHASE III CLINICAL TRIAL

Paiva, B.; Martínez-Cuadrón, D.; Bergua, J.M.; More

HemaSphere. 3(S1):59, June 2019.

PF541 TRANSCRIPTIONAL ALTERATIONS OF HEMATOPOIETIC STEM CELLS IN MYELODYSPLASTIC SYNDROMES

Ezponda, T.; Romero, J.P.; Ainciburu, M.; More

HemaSphere. 3(S1):223, June 2019.

PF567 CHROMATIN ACTIVATION AS A UNIFYING PRINCIPLE UNDERLYING PATHOGENIC MECHANISMS IN MULTIPLE MYELOMA

Ordoñez, R.; Kulis, M.; Russiñol, N.; More

HemaSphere. 3(S1):236, June 2019.

PF609 HEAVY&LIGHT CHAIN MONITORING IN HIGH RISK SMOLDERING MULTIPLE MYELOMA PATIENTS INCLUDED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MINIMAL RESIDUAL DISEASE IMWG RESPONSE ASSESSMENT

Puig, N.; Contreras, T.; Paiva, B.; More

HemaSphere. 3(S1):258, June 2019.

S871 CURATIVE STRATEGY (GEM-CESAR) FOR HIGH-RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT-ASCT, CONSOLIDATION WITH KRD AND MAINTENANCE WITH RD

Mateos, M.-V.; Martínez-López, J.; Rodríguez-Otero, P.; More

HemaSphere. 3(S1):390, June 2019.

PS1348 DETAILED PHENOTYPIC, MOLECULAR AND FUNCTIONAL PROFILING OF MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN THE TUMOR IMMUNE MICRO-ENVIRONMENT (TIME) OF MULTIPLE MYELOMA (MM)

Pérez, C.; Botta, C.; Zabaleta, A.; More

HemaSphere. 3(S1):615-616, June 2019.

PS1351 CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL

Ubieto, A. Jiménez; Martinez-Lopez, J.; Paiva, B.; More

HemaSphere. 3(S1):617, June 2019.

PS1352 DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS

Puig, N.; Paíno, T.; Pérez, J.J.; More

HemaSphere. 3(S1):617-618, June 2019.

Author:
Pakdaman, S.

S906 PRECLINICAL EVALUATION OF THE PRESERVATION OF RED BLOOD CELL CONCENTRATES IN HYPOXIA BY HYPOXIC STORAGE TECHNOLOGY FOR TRANSFUSION IN SICKLE CELL DISEASE.

Bencheikh, L.; Nguyen, K.-A.; Chadebech, P.; More

HemaSphere. 3(S1):409, June 2019.

Author:
Pal, D.
Author:
Pal, K.

S129 TP53 SOMATIC MUTATIONS AS PRE-LEUKEMIC EVENTS IN ACUTE LYMPHOBLASTIC LEUKEMIA

Chitadze, G.; Stengel, A.; John-Klaua, C.; More

HemaSphere. 3(S1):16-17, June 2019.

PF175 MULTICENTRE STANDARDIZATION OF MINIMAL RESIDUAL DISEASE DETECTION AND QUANTITATION USING THE EUROCLONALITY-NGS ASSAY

Svaton, M.; Fronkova, E.; Kotrova, M.; More

HemaSphere. 3(S1):39-40, June 2019.

Author:
Pala, C.
Author:
Palacio, C.
Author:
Palandri, F.

PF674 OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS

Palandri, F.; Breccia, M.; Bonifacio, M.; More

HemaSphere. 3(S1):290, June 2019.

PF695 ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP

Lucchini, E.; Palandri, F.; Volpetti, S.; More

HemaSphere. 3(S1):302, June 2019.

PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS

Barbui, T.; Ghirardi, A.; Masciulli, A.; More

HemaSphere. 3(S1):667-668, June 2019.

PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

Mora, B.; Guglielmelli, P.; Rumi, E.; More

HemaSphere. 3(S1):671, June 2019.

S1626 INCOMPLETE COUNT RECOVERY IN PATIENTS WITH COMPLETE REMISSION PRIOR TO ALLOGENEIC HCT FOR AML IS ASSOCIATED WITH A HIGH NON-RELAPSE MORTALITY WITHOUT AN INCREASED RELAPSE RISK

Innes, A.; Wooley, P.; Szydlo, R.; More

HemaSphere. 3(S1):751-752, June 2019.

PB2096 HIGH PLASMA CELL PROLIFERATIVE INDEX IS ASSOCIATED WITH A DOMINANT EXPANSION OF A SINGLE IMMUNOPHENOTYPIC SUBCLONE AND PREDICTS RESPONSE TO LENALIDOMIDE/DEXAMETHASONE IN RELAPSED MULTIPLE MIELOMA

Arranz, E.; Palao, H. Sarmiento; Rodriguez, V. Díaz; More

HemaSphere. 3(S1):944, June 2019.

Author:
Palazzi, G.